How to drive regulatory success with effective medical writing
Submitting a dossier to the EMA or MHRA is [...]
How to manage serious adverse events in early-phase clinical trials
Reporting serious adverse events (SAE) is integral to running [...]
Your essential checklist for an effective regulatory submission
Bringing a new drug to market is a complex, [...]
10 common pharmacovigilance inspection findings and their implications
Pharmacovigilance (PV) plays a crucial role in assuring patient [...]
Why you need a specialist for regulatory submissions in rare disease clinical trials
The path to regulatory approval for rare disease treatments [...]
FDA orphan drug designation vs. EMA orphan drug designation
Orphan drug designation (ODD) is granted to drugs that [...]
What you need to know about different types of regulatory submissions
Regulatory submissions are essential for obtaining the necessary approvals [...]
Orphan drug designation criteria, benefits and the EMA new drug approval process
Treatments intended for rare diseases may not be profitable [...]